<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap9" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>9</ChapterID>
          <ChapterNumber>Chapter 9</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_9</ChapterDOI>
          <ChapterSequenceNumber>9</ChapterSequenceNumber>
          <ChapterTitle Language="En">Androgen Deprivation Therapy</ChapterTitle>
          <ChapterFirstPage>101</ChapterFirstPage>
          <ChapterLastPage>107</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_9" CorrespondingAffiliationID="Aff1_9">
              <AuthorName DisplayOrder="Western">
                <GivenName>Nima</GivenName>
                <FamilyName>Sharifi</FamilyName>
              </AuthorName>
              <Contact>
                <Email>nima.sharifi@utsouthwestern.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_9">
              <OrgDivision>Division of Hematology/Oncology</OrgDivision>
              <OrgName>University of Texas Southwestern Medical Center</OrgName>
              <OrgAddress>
                <City>Dallas</City>
                <State>TX</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_9" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist. Adverse effects include hot flashes, sexual dysfunction, increased risk of fracture, metabolic syndrome and increased risk of cardiovascular events. The timing of administration of early versus late ADT is still contentious and under active debate. Intermittent ADT may be an alternative to continuous testosterone depletion; although intermittent therapy decreases adverse effects, the comparative efficacy of each is still under active study. The study of germline genetic determinants in response to ADT is in its early phase. However, these studies have the potential to allow for patient selection for the type and timing of ADT.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Androgen deprivation therapy</Keyword>
            <Keyword>Androgens</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Testosterone</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Survival and proliferation of prostate cancer is entirely dependent on the availability of androgens and expression of the androgen receptor (AR). The testes are the primary source of androgens and release testosterone into systemic circulation [<CitationRef CitationID="CR1_9">1</CitationRef>]. Once serum testosterone reaches prostatic tissue, it is converted into dihydrotestosterone, the chief and most potent natural ligand and stimulus for AR [<CitationRef CitationID="CR2_9">2</CitationRef>, <CitationRef CitationID="CR3_9">3</CitationRef>]. The molecular basis of signaling through the AR transcription factor is discussed in further detail in <ExternalRef>
                <RefSource>Chap. 5</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_5" TargetType="DOI"/>
              </ExternalRef> and is beyond the scope of this section. The near-ubiquitous expression of AR in prostate cancer cases provides the foundation for the efficacy of androgen deprivation therapy (ADT) as the frontline treatment for advanced prostate cancer. ADT is defined herein as androgen depletion with medical or surgical castration. The beneficial effects of ADT with surgical castration and the administration of estrogens were first noted by Huggins and Hodges in 1941 [<CitationRef CitationID="CR4_9">4</CitationRef>]. Although the science behind the understanding of hormonal therapy has made remarkable progress, the efficacy of standard hormonal therapy for metastatic prostate cancer has not changed significantly for over nearly 70 years. However, recent investigations into the timing and context of ADT, progress with novel agents in clinical trials, and a better understanding of the predisposition of some patients to castration-resistance promise the development of a standard of care that will deliver improved survival and better outcomes for prostate cancer patients.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Androgen Deprivation Therapy</Heading>
            <Para TextBreak="No">ADT, in current practice, is administered through medical or surgical castration [<CitationRef CitationID="CR5_9">5</CitationRef>]. Surgical castration with orchiectomy is generally a low surgical risk procedure [<CitationRef CitationID="CR6_9">6</CitationRef>]. However, it is not favored by many men, given the psychological impact and the availability of a medical alternative. Medical castration is attained with the administration of gonadotropin-releasing hormone agonists (GnRH-As). Leuprolide acetate and goserelin acetate are two commonly used GnRH-As that are equally effective for the induction of medical castration [<CitationRef CitationID="CR7_9">7</CitationRef>]. The hypothalamus releases endogenous GnRH in a pulsatile manner and its corresponding receptor is expressed in the anterior pituitary [<CitationRef CitationID="CR8_9">8</CitationRef>]. GnRH receptor stimulation induces the release of luteinizing hormone (LH) from the anterior pituitary into the systemic circulation, which then acts upon the testes to induce testosterone secretion. The stimulatory effect of GnRH on LH release from the anterior pituitary is dependent on the pulsatile nature of GnRH secretion. Therefore, continuous stimulation of the anterior pituitary by administration of exogenous GnRH-As effectively inhibits LH release, which, in turn, suppresses testosterone release from the testes (Fig. <InternalRef RefID="Fig1">9.1</InternalRef>) [<CitationRef CitationID="CR6_9">6</CitationRef>, <CitationRef CitationID="CR9_9">9</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 9.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Hormonal interventions and endocrine axis in prostate cancer. DHT indicates dihydrotestosterone and LH, luteinizing hormone. Asterisk indicates that it is no longer available for new patients in the United States. Illustration based on the original concept by Lydia Kibiuk. Reprinted from [<CitationRef CitationID="CR5_9">5</CitationRef>]. Copyright ©2005 American Medical Association. All rights reserved</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_9">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_9_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Although GnRH-As generally lead to castrate levels of serum testosterone by 3 weeks after starting therapy, the initiation of drug administration leads to an initial stimulatory effect on the pituitary and generates a testosterone surge. A GnRH-A induced surge may lead to a twofold increase in testosterone, become evident from 2–3 days after initiation of therapy, and last up to 20 days [<CitationRef CitationID="CR10_9">10</CitationRef>]. This surge of androgens induces a growth-stimulatory effect on prostate cancer cells and may lead to a detrimental “flare” reaction in patients who have metastatic disease, which can increase bone pain at sites of metastasis. Furthermore, patients with vertebral metastases may develop spinal cord compression; those at risk may develop urinary obstruction, and cardiovascular events may occur due to hypercoagulability [<CitationRef CitationID="CR11_9">11</CitationRef>]. Concomitant administration of an AR antagonist with the initiation of GnRH-A and continuation for 2–4 weeks will block the effects of the testosterone surge and the “flare” reaction that follows [<CitationRef CitationID="CR12_9">12</CitationRef>]. The testosterone surge may also be avoided by the use of GnRH antagonists as an alternative to agonists [<CitationRef CitationID="CR10_9">10</CitationRef>].</Para>
            <Para TextBreak="No">Serum testosterone levels less than 50 ng/dL (1.7 nmol/L) are generally accepted as being in the range of castration [<CitationRef CitationID="CR13_9">13</CitationRef>]. However, the current understanding of AR- and androgen-signaling-dependent growth of prostate cancer [<CitationRef CitationID="CR1_9">1</CitationRef>, <CitationRef CitationID="CR14_9">14</CitationRef>, <CitationRef CitationID="CR15_9">15</CitationRef>] dictates that men should achieve a testosterone level as low as possible to optimize therapy. Most men will attain a testosterone level below 20 ng/dL (0.7 nmol/L), which has also been suggested as an alternative lower level that should be achieved for optimal therapy [<CitationRef CitationID="CR16_9">16</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Timing of ADT</Heading>
            <Para TextBreak="No">While considering the initiation of any form of therapy, the relative balance of risks and benefits must be weighed. These risks and predispositions to adverse events must be similarly considered before the commencement of ADT. The risks of ADT include hot flashes [<CitationRef CitationID="CR17_9">17</CitationRef>], osteoporosis with an increased risk of fracture [<CitationRef CitationID="CR18_9">18</CitationRef>], the metabolic syndrome [<CitationRef CitationID="CR19_9">19</CitationRef>, <CitationRef CitationID="CR20_9">20</CitationRef>], sexual dysfunction [<CitationRef CitationID="CR21_9">21</CitationRef>], and an increased risk of cardiovascular events [<CitationRef CitationID="CR22_9">22</CitationRef>]. The potential benefit of early ADT is that treatment is initiated with a lower tumor burden, with a correspondingly lower number of cells that have the capacity for being resistant to therapy. Early ADT can be defined in several clinical contexts, including (1) metastatic disease before symptoms arise, (2) biochemical recurrence after local therapy with prostate-specific antigen (PSA) rise without evidence of metastatic disease, (3) watchful waiting for patients with local disease who are not candidates for local therapy, and (4) pelvic lymph node involvement at radical prostatectomy. In addressing the debate between early and late ADT in the metastatic setting, the Medical Research Council conducted a randomized trial of immediate ADT versus deferred treatment until an indication arose for 934 men with locally advanced or asymptomatic metastatic prostate cancer [<CitationRef CitationID="CR23_9">23</CitationRef>]. Men in the immediate ADT arm had a lower probability of death from prostate cancer (62% vs. 71%; <Emphasis Type="Italic">P</Emphasis>= 0.001) and lower rates of extraskeletal metastasis (7.9% vs. 11.8%; <Emphasis Type="Italic">P</Emphasis> &lt; 0.05), pathological fracture (2.3% vs. 4.5%; not statistically significant), ureteral obstruction (7.0% vs. 11.8%; <Emphasis Type="Italic">P</Emphasis> &lt; 0.025), and spinal cord compression (1.9% vs. 4.9%; <Emphasis Type="Italic">P</Emphasis> &lt; 0.025). Although outcomes were more favorable in the immediate ADT arm, a weakness of this study is that 29 men in the deferred ADT arm died without treatment with ADT.</Para>
            <Para TextBreak="No">Pelvic lymph node involvement without bone metastasis for men who have had surgical removal of the prostate is another clinical context of early ADT. Messing et al. [<CitationRef CitationID="CR24_9">24</CitationRef>, <CitationRef CitationID="CR25_9">25</CitationRef>] completed a randomized clinical trial of immediate adjuvant ADT versus observation of men who underwent radical prostatectomy and were found to have disease involving the pelvic lymph nodes. A significantly higher proportion of men who were randomized to observation died compared to men in the immediate ADT arm with a median follow-up of 10 years (51% vs. 28%; <Emphasis Type="Italic">P</Emphasis> = 0.025). This suggests the possibility that early ADT with lower, minimal tumor burden may provide a treatment advantage.</Para>
            <Para TextBreak="No">Three recent randomized clinical trials of early versus deferred ADT have been completed in the setting of men who were not candidates for local therapy or who did not get local therapy because of the presence of pelvic lymph node involvement. EORTC 30846 included 302 patients with node positive disease and showed a trend for increased survival with early ADT [<CitationRef CitationID="CR26_9">26</CitationRef>]. However, this study was underpowered and the survival difference was not statistically significant. The SAKK 08/88 study enrolled 197 patients who were not candidates for local therapy and showed a non-statistically significant difference in deaths due to prostate cancer (<Emphasis Type="Italic">P</Emphasis> = 0.09) in the immediate ADT group versus the deferred ADT group (76% vs. 63%), with no difference in median overall survival (5.2 vs. 4.4 years; <Emphasis Type="Italic">P</Emphasis> = 0.96) [<CitationRef CitationID="CR27_9">27</CitationRef>]. EORTC 30891, which enrolled 985 patients who were not candidates for local therapy, did show an increase in overall survival for patients treated with immediate ADT, with an overall survival hazard ratio of 1.25, 95% CI, 1.05–1.48 [<CitationRef CitationID="CR28_9">28</CitationRef>]. Perplexingly, this difference seemed to be due to nonprostate cancer related deaths. One fourth of the men in the deferred ADT arm died without ever requiring ADT. A large population-based cohort study involving 19,271 men who did not receive definitive local therapy found that primary ADT is not associated with improved survival [<CitationRef CitationID="CR29_9">29</CitationRef>], and similar to EORTC 30891, men with lower risk cancer treated with early ADT may have a worse cancer-specific survival.</Para>
            <Para TextBreak="No">Yet another clinical scenario is that of patients who have a PSA recurrence only, after failure of surgery or radiation for the treatment of localized disease. A single-institution study of men with PSA recurrence only after radical prostatectomy suggests that these men have a relatively indolent history, with a median actuarial time to metastasis of 8 years after PSA recurrence [<CitationRef CitationID="CR30_9">30</CitationRef>]. However, about half of the men in this study with a Gleason score of 8–10 who had a biochemical recurrence within 2 years were free of metastasis at 3 years. The shorter time to metastasis in patients with high Gleason scores suggests that a subgroup of men with biochemical recurrence who have a more aggressive clinical course may potentially benefit from early treatment. Nonetheless, there are no data from prospective randomized clinical trials to guide the treatment of men with PSA recurrence after the failure of local therapy. Furthermore, the 2007 American Society of Clinical Oncology Practice Panel does not make a strong recommendation for the institution of early ADT for patients with metastatic or progressive prostate cancer (Table <InternalRef RefID="Tab1">9.1</InternalRef>) [<CitationRef CitationID="CR31_9">31</CitationRef>].<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 9.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>2007 updated American society of clinical oncology practice guidelines for initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Question</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Recommendation</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>What are the standard initial treatment options?</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Bilateral orchiectomy or GnRH agonist</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Are AR antagonists as effective as orchiectomy or GnRH agonist?</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Nonsteroidal antiandrogen monotherapy, but not steroidal antiandrogen monotherapy may be discussed as an alternative</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Is combined androgen blockade better than androgen deprivation therapy alone?</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Combined androgen blockage should be considered as an alternative</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Does early androgen deprivation therapy lead to better outcomes than deferred androgen deprivation?</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>There is no overall survival advantage for early androgen deprivation therapy, and hence, the panel cannot strongly recommend early treatment</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Is there a role for intermittent androgen deprivation therapy?</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>There are insufficient data to recommend use of intermittent androgen deprivation outside clinical trials</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Androgen Deprivation Therapy, AR Antagonist, or Both?</Heading>
            <Para TextBreak="No">In principle, two ways of preventing stimulation of AR-mediated growth are to deplete levels of the ligand or directly block AR with competitive antagonists. Bicalutamide, nilutamide, and flutamide are three nonsteroidal AR antagonists in clinical use [<CitationRef CitationID="CR5_9">5</CitationRef>]. Although there is, without question, a mechanistic difference between these two methods of blocking androgen function, comparisons of ADT versus monotherapy with nonsteroidal anti-androgens do not show a significant difference in overall survival [<CitationRef CitationID="CR32_9">32</CitationRef>]. However, nonsteroidal anti-androgens may have a more desirable side-effect profile than ADT. ASCO practice guidelines suggest that nonsteroidal anti-androgen monotherapy may be discussed as an alternative to ADT [<CitationRef CitationID="CR33_9">33</CitationRef>].</Para>
            <Para TextBreak="No">The concomitant use of ADT and therapy with AR antagonists to both suppress testicular androgen production and directly antagonize AR at the level of the tumor is termed combined androgen blockade (CAB). Numerous clinical trials have compared the utility of ADT alone versus CAB. A meta-analysis of 27 randomized trials comparing ADT with CAB shows that there is a 2–3% 5-year survival benefit with the use of CAB [<CitationRef CitationID="CR34_9">34</CitationRef>]. However, this benefit is limited to the use of nonsteroidal antiandrogens, and it was found that the sum total of the data on CAB with the steroidal anti-androgen, cyproterone acetate, suggested less favorable outcomes. A recent study of GnRH-A versus CAB in Japanese men showed a significantly improved overall survival (63.4% vs. 75.3%; <Emphasis Type="Italic">P</Emphasis> = 0.0425) at a median follow-up of over 5 years [<CitationRef CitationID="CR35_9">35</CitationRef>]. The survival benefit of CAB with nonsteroidal anti-androgens comes at a significant cost, which amounts to a price of $1 million per quality-adjusted life-year [<CitationRef CitationID="CR33_9">33</CitationRef>]. However, the most recent ASCO practice guidelines suggest that CAB should be considered as an alternative to ADT alone [<CitationRef CitationID="CR31_9">31</CitationRef>]. Although numerous well-conducted randomized trials have been done to compare ADT with CAB and the benefit of CAB has been analyzed with varying methods, the issue of CAB is almost certain to become once again unsettled. Novel and more potent AR antagonists are in early clinical trials [<CitationRef CitationID="CR36_9">36</CitationRef>–<CitationRef CitationID="CR38_9">38</CitationRef>], and as these agents undergo further clinical development, the issue of the utility of CAB with these new agents will undoubtedly be revisited. Furthermore, the development of new and more potent agents that inhibit androgen synthesis, such as abiraterone acetate [<CitationRef CitationID="CR39_9">39</CitationRef>], offer the opportunity to apply these agents at earlier stages, along with ADT. If these agents provide benefit when given concomitantly along with ADT, they may serve to redefine the meaning of CAB.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Intermittent Androgen Deprivation</Heading>
            <Para TextBreak="No">An alternative to continuous ADT with GnRH-A is intermittent androgen deprivation by alternating between periods of testosterone depletion and testosterone recovery. Such an approach is feasible, and testosterone recovery for limited periods of time may allow the patient to enjoy a lessening of adverse effects associated with ADT [<CitationRef CitationID="CR40_9">40</CitationRef>]. A randomized prospective study of intermittent versus continuous CAB with GnRH-A plus bicalutamide was conducted with 335 patients with disease involving lymph nodes or distant metastasis [<CitationRef CitationID="CR41_9">41</CitationRef>]. Off treatment periods were greater than 40% in the intermittent ADT arm, and this was associated with more favorable sexual activity. There was no significant difference in median time to death between the two treatment arms (<Emphasis Type="Italic">P</Emphasis> = 0.658). SWOG 9346 is an ongoing trial of 1,345 men with metastatic prostate cancer who received induction ADT with GnRH-A and bicalutamide for 7 months [<CitationRef CitationID="CR42_9">42</CitationRef>]. 965 men who achieved a PSA level of 4 ng/mL or less have been randomized to continuous ADT or intermittent ADT. While this study is ongoing and the outcomes with continuous versus intermittent ADT have yet to be determined, it is clear that PSA nadir is a strong predictor of survival. PSA nadirs of &lt;0.2, &lt;4, and &gt;4 ng/mL are associated with median survival times of 75, 44, and 13 months [<CitationRef CitationID="CR42_9">42</CitationRef>]. Thus, PSA nadirs after induction ADT may eventually be used to select patients for a specific therapy [<CitationRef CitationID="CR43_9">43</CitationRef>]. However, the final results of this trial are awaited before determining the exact utility of this prognostic value.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Genetic Determinants of Response to Androgen Deprivation</Heading>
            <Para TextBreak="No">Prostate cancer is a heterogeneous disease, and variables attributable to a specific patient take part in determining the course of the disease and the response to therapy. The response and response duration to ADT is tremendously variable. Ultimately, it would be desirable to administer hormonal therapy that is tailored for a patient and the specific molecular features of an individual prostate tumor. It is clear that after ADT is administered for metastatic prostate cancer, the evolution of the tumor into castration-resistant disease involves the reactivation of AR [<CitationRef CitationID="CR15_9">15</CitationRef>, <CitationRef CitationID="CR44_9">44</CitationRef>]. However, it is difficult to apply the delineation of these somatic genetic or epigenetic changes that occur within the tumor to prognosticate response or response duration to ADT. In contrast, defining germline genetic polymorphisms that bear some responsibility in determining the response to ADT may have utility in stratifying patients in terms of the likelihood of response [<CitationRef CitationID="CR45_9">45</CitationRef>]. One would suspect that germline genetic factors would play some part in defining the response to ADT, and there is recent evidence to suggest that this is indeed the case. One study examined polymorphisms associated with 20 genes that are implicated in androgen metabolism in 529 patients who underwent ADT for advanced prostate cancer [<CitationRef CitationID="CR46_9">46</CitationRef>]. Three single nucleotide polymorphisms (SNP) that are associated with genes involved in androgen metabolism were found to be associated with the duration of response to ADT. These SNPs were found upstream of or within the introns of these genes and therefore are not known protein coding sequences. The significance of these polymorphisms may be an involvement in the regulation of gene expression. The first gene is <Emphasis Type="Italic">CYP19A1</Emphasis>, which encodes for aromatase, which converts testosterone to estradiol [<CitationRef CitationID="CR47_9">47</CitationRef>]. The second gene is <Emphasis Type="Italic">HSD3B1</Emphasis>, which is involved in the generation of androstenedione and testosterone from adrenal precursors [<CitationRef CitationID="CR48_9">48</CitationRef>]. The third gene is <Emphasis Type="Italic">HSD17B4</Emphasis>, which regulates the interconversion of active to inactive androgens and estrogens [<CitationRef CitationID="CR49_9">49</CitationRef>].</Para>
            <Para TextBreak="No">A second study of 68 patients began with the observation that a testosterone transporter has protein coding SNPs that confer changes in cellular testosterone uptake activity [<CitationRef CitationID="CR50_9">50</CitationRef>]. The <Emphasis Type="Italic">SLCO1B3</Emphasis> gene encodes for the OATP1B3 transporter protein and has two amino acid-changing SNPs that are in complete linkage disequilibrium. It is important to note that the <Emphasis Type="Italic">SLCO1B3</Emphasis> SNPs associated with increased testosterone uptake are found more frequently in African-Americans compared to Caucasians [<CitationRef CitationID="CR51_9">51</CitationRef>] and that because of the small numbers, the analysis in this study on duration of response to ADT was limited to Caucasian patients. OATP1B3 is overexpressed in prostate cancer compared to benign prostate [<CitationRef CitationID="CR50_9">50</CitationRef>]. Patients with advanced prostate cancer treated with ADT, who have one or two germline copies of the more active OATP1B3 transporter, have a shorter time to castration resistance compared to patients who have two copies of the less-active transporter [<CitationRef CitationID="CR52_9">52</CitationRef>].</Para>
            <Para TextBreak="No">Both of these studies that suggest germline polymorphisms of genes involved in androgen metabolism and transport influence of the response duration to ADT, require confirmation in independent patient cohorts. If confirmed, such data can be used not only to determine the likelihood of response to ADT, but also to tease out a subset of patients who would benefit from early hormonal therapy tailored to their specific germline. For example, the patients who have more active testosterone import activity may be the ones who specifically benefit from CAB with upfront AR antagonist because they have higher intracellular testosterone concentrations despite castrate levels of serum testosterone.</Para>
          </Section1>
          <Section1 ID="Sec7" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">ADT with medical or surgical castration is the mainstay of the treatment of advanced prostate cancer. There may be a small benefit of CAB with the use of nonsteroidal AR antagonists, and this method may also be considered. However, AR antagonists with increased AR binding affinity and potency are in early clinical trials and may redefine the role of CAB. The debate on administering early vs. late ADT for advanced prostate cancer continues. Although there is no data for the use of ADT in patients with biochemical relapse after local therapy, the rationale for delaying ADT for patients with asymptomatic metastatic disease is more tenuous and may only be considered for select patients with careful monitoring for disease progression. Although there is data to support the use of intermittent androgen deprivation for patients with advanced disease, a large ongoing trial is poised to provide more definitive results and may also identify those patients who are appropriate candidates for this alternative to continuous ADT. The study of germline genetic polymorphisms in the androgen pathway that contribute to determining the response to ADT is just beginning. Future directions should lead to the matching of a patient’s molecular features and other prognostic factors with a specific type and timing of hormonal therapy to optimize the benefits and minimize adverse effects of treatment.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_9.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_9">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McPhaul</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Mechanisms of prostate cancer progression to androgen independence</ArticleTitle>
                <JournalTitle>Best Pract Res Clin Endocrinol Metab</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>373</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>18471793</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.beem.2008.02.006</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslygtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008;22:373–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_9">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Bruchovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1968</Year>
                <ArticleTitle Language="En">The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>243</VolumeID>
                <FirstPage>5953</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>5696629</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaF1cXltVent7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 1968;243:5953–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_9">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Steroid 5 alpha-reductase: two genes/two enzymes</ArticleTitle>
                <JournalTitle>Annu Rev Biochem</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>25</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>7979239</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.bi.63.070194.000325</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXitlCitQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_9">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huggins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CV</Initials>
                  <FamilyName>Hodges</FamilyName>
                </BibAuthorName>
                <Year>1941</Year>
                <ArticleTitle Language="En">Studies on prostate cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>293</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaH3MXkvVCrtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huggins C, Hodges CV. Studies on prostate cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_9">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>294</VolumeID>
                <FirstPage>238</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>16014598</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.294.2.238</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtlSlt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_9">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Hormonal therapy: historical perspective to future directions</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>3</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12667881</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(02)02393-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61:3–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_9">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Fujii</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yonese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kawakami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yamamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Okubo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Fukui</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>1096</FirstPage>
                <LastPage>100</LastPage>
                <Occurrence Type="PID">
                  <Handle>18190637</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2007.07374.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtlSktLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int 2008;101:1096–100.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_9">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Engel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Schally</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone</ArticleTitle>
                <JournalTitle>Nat Clin Pract Endocrinol Metab</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>157</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>17237842</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpendmet0399</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhvVWrsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_9">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Limonta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Montagnani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Moretti</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>709</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>11281820</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1517/13543784.10.4.709</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXis1Kjs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10:709–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_9">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Poppel</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Nilsson</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Testosterone surge: rationale for gonadotropin-releasing hormone blockers?</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>71</VolumeID>
                <FirstPage>1001</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18407326</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2007.12.070</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008;71:1001–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_9">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Is the flare phenomenon clinically significant?</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>5</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11502435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(01)01235-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mvlslegsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58:5–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_9">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Kuhn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Billebaud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Navratil</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>321</VolumeID>
                <FirstPage>413</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>2503723</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM198908173210701</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1MzksVWgtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_9">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>3461</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10550143</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FhvValsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_9">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tomlins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mehra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Integrative molecular concept modeling of prostate cancer progression</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>39</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17173048</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng1935</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlGktLjN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_9">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Molecular biology of the androgen receptor</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>3001</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>12089231</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2002.10.018</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xlslyrt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_9">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Oefelein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Feng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Scolieri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ricchiutti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MI</Initials>
                  <FamilyName>Resnick</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>1021</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>11113751</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(00)00793-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M7hsFersQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_9">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Holzbeierlein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>McLaughlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Thrasher</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Complications of androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>Curr Opin Urol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>177</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>15069309</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00042307-200405000-00007</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004;14:177–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_9">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VB</Initials>
                  <FamilyName>Shahinian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YF</Initials>
                  <FamilyName>Kuo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Freeman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Goodwin</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Risk of fracture after androgen deprivation for prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>352</VolumeID>
                <FirstPage>154</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>15647578</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041943</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXksFajuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_9">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer: new concepts and concerns</ArticleTitle>
                <JournalTitle>Curr Opin Endocrinol Diabetes Obes</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>247</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>17940447</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/MED.0b013e32814db88c</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14:247–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_9">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy: monitoring and managing the complications</ArticleTitle>
                <JournalTitle>Hematol Oncol Clin North Am</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>909</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>16861122</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.hoc.2006.03.013</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 2006;20:909–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_9">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>Fowler</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>McNaughton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Walker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Elliott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Barry</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>287</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>12124828</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.10656</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fowler FJ, Jr., McNaughton CM, Walker CE, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_9">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shahani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Braga-Basaria</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Basaria</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>2042</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18349064</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2007-2595</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXntFamsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_9">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>The Medical Research Council Prostate Cancer Working Party Investigators Group</InstitutionalAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>235</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410X.1997.d01-6840.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_9">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Messing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sarosdy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>341</VolumeID>
                <FirstPage>1781</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10588962</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199912093412401</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FlsFOltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_9">
              <CitationNumber>25.</CitationNumber>
              <BibUnstructured>Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenoectomy in men with node-positive prostate cancer: results at 10 years of EST 3886. In: American Urological Association meeting. Chicago, IL; 2003.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_9">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FH</Initials>
                  <FamilyName>Schroder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Kurth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Fossa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Early versus delayed endocrine treatment of pN1–3 M0 prostate cancer without local treatment of the primary tumor: results of European organisation for the research and treatment of cancer 30846–a phase III study</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>172</VolumeID>
                <FirstPage>923</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15310999</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000135742.13171.d2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European organisation for the research and treatment of Cancer 30846 – a phase III study. J Urol 2004;172:923–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_9">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>UE</Initials>
                  <FamilyName>Studer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Hauri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hanselmann</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>4109</FirstPage>
                <LastPage>18</LastPage>
                <Occurrence Type="PID">
                  <Handle>15483020</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.11.514</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004;22:4109–18.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_9">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>UE</Initials>
                  <FamilyName>Studer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Whelan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Albrecht</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>1868</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>16622261</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.04.7423</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_9">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Lu-Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Albertsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DF</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Survival following primary androgen deprivation therapy among men with localized prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>300</VolumeID>
                <FirstPage>173</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>18612114</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.300.2.173</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXosVWqt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_9">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Pound</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Partin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Pearson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Natural history of progression after PSA elevation following radical prostatectomy</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>281</VolumeID>
                <FirstPage>1591</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10235151</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.281.17.1591</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3kvFagsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_9">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Loblaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Virgo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nam</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1596</FirstPage>
                <LastPage>605</LastPage>
                <Occurrence Type="PID">
                  <Handle>17404365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.10.1949</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsVynurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline. J Clin Oncol 2007;25:1596–605.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_9">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Seidenfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Samson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Hasselblad</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis</ArticleTitle>
                <JournalTitle>Ann Intern Med</JournalTitle>
                <VolumeID>132</VolumeID>
                <FirstPage>566</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>10744594</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.7326/0003-4819-132-7-200004040-00009</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXis1Sjsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_9">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Loblaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Mendelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Talcott</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>2927</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>15184404</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.04.579</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Loblaw DA, Mendelson DS, Talcott JA, et al. American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_9">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>Prostate Cancer Trialists’ Collaborative Group</InstitutionalAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>355</VolumeID>
                <FirstPage>1491</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(00)02163-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_9">
              <CitationNumber>35.</CitationNumber>
              <BibUnstructured>Akaza H, Hinotsu S, Usami M, et al. Extended analyses: Combined androgen blockade (CAB) therapy with bicalutamide vs. leuteinizing hormone-releasing hormone agonist (LHRHa) monotherapy in Japanese men with untreated advanced prostate cancer. In: American society of clinical oncology Annual Meeting. Chicago, IL; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_9">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Year>2010</Year>
                <ArticleTitle Language="En">Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>375</VolumeID>
                <FirstPage>1437</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>20398925</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(10)60172-9</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BC3cXltFOmsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_9">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Drug insight: role of the androgen receptor in the development and progression of prostate cancer</ArticleTitle>
                <JournalTitle>Nat Clin Pract Oncol</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>236</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>17392714</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncponc0765</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjs12rsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_9">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Secondary hormonal therapy for prostate cancer: what lies on the horizon?</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>271</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>17922868</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2007.07236.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXis1amt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int 2008;101:271–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_9">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Hsieh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Novel concepts in androgen receptor blockade</ArticleTitle>
                <JournalTitle>Cancer J</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>11</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>18303477</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/PPO.0b013e318161d13e</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXivF2jtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J 2008;14:11–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_9">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Bhandari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Crook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Should intermittent androgen deprivation be used in routine clinical practice?</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>8212</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16278475</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.03.2557</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005;23:8212–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_9">
              <CitationNumber>41.</CitationNumber>
              <BibUnstructured>Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. In: American society of clinical oncology Annual Meeting. Chicago, IL; 2007.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_9">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>3984</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>16921051</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.4246</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_9">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Heidenreich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Aus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bolla</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">EAU guidelines on prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>68</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>17920184</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2007.09.002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_9">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Mostaghel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Montgomery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The basic biochemistry and molecular events of hormone therapy</ArticleTitle>
                <JournalTitle>Curr Urol Rep</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>224</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>17459272</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s11934-007-0010-z</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mostaghel EA, Montgomery RB, Lin DW. The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep 2007;8:224–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_9">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The genetics of castration-resistant prostate cancer: What can the germline tell us?</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>4691</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>18676736</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-08-0453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpt1ejsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Dahut W, Figg WD. The genetics of castration-resistant prostate cancer: What can the germline tell us? Clin Cancer Res 2008;14:4691–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_9">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>842</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18281655</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.13.6804</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_9">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Modugno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Weissfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>3092</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11595700</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvF2ku70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_9">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Hawkins</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>1784</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11912155</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XisVSitrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evaul K, Li R, Papari-Zareei M, Auchus RJ, and Sharifi N. 3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010. In press.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_9">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Launoit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Adamski</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>227</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>10343282</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/jme.0.0220227</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Launoit Y, Adamski J. Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. J Mol Endocrinol 1999;22:227–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_9">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>3312</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519758</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-4118</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmslygsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_9">
              <CitationNumber>51.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Marsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Scott-Horton</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>76</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>17186002</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.clpt.6100011</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aqsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_9">
              <CitationNumber>52.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>102</VolumeID>
                <FirstPage>617</FirstPage>
                <LastPage>621</LastPage>
                <Occurrence Type="PID">
                  <Handle>18537956</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2008.07629.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFSlurjE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008;102:617–621.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
